Reflections on medical oncology: 25 years of clinical trials - Where have we come and where are we going?

被引：40

作者：

Booth, Christopher M. ^{[1
]}

Tannock, Ian ^{[2
]}

机构：

[1] Queens Univ, Natl Canc Inst, Canada Clin Trials Grp, Kingston, ON, Canada

[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 01期

关键词：

D O I：

10.1200/JCO.2007.13.8156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：6 / 8

页数：3

共 19 条

[1] Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings [J].

Bedard, Philippe L. ;

Krzyzanowska, Monika K. ;

Pintilie, Melania ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) :3482-3487

[2] Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].

Begg, C ;

Cho, M ;

Eastwood, S ;

Horton, R ;

Moher, D ;

Olkin, I ;

Pitkin, R ;

Rennie, D ;

Schulz, KF ;

Simel, D ;

Stroup, DF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639

[3]

BOOTH CM, 2007, J CLIN ONCOL S, V25, pS325

[4] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[5] The uncertainty principle and industry-sponsored research [J].

Djulbegovic, B ;

Lacevic, M ;

Cantor, A ;

Fields, KK ;

Bennett, CL ;

Adams, JR ;

Kuderer, NM ;

Lyman, GH .

LANCET, 2000, 356 (9230) :635-638

[6] Trends in clinical trials reports in common cancers between 1989 and 2000 [J].

Hillner, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1850-1858

[7] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[8] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[9]

JOLY F, ANN ONCOL

[10] Quality of abstracts describing randomized trials in the Proceedings of American society of Clinical Oncology meetings: Guidelines for improved reporting [J].

Krzyzanowska, MK ;

Pintilie, M ;

Brezden-Masley, C ;

Dent, R ;

Tannock, IF .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1993-1999

← 1 2 →